Prognosis and treatment response stratification according to loss of proofreading (LOP) <i>POLE</i> variants
Identifying the subset of <i>POLE</i> mutations that cause LOP is critical to distinguish patients likely to respond to immunotherapy. Patients with CRC with LOP <i>POLE</i> mutant tumors experienced deep, sustained response to immunotherapy but were resistant to standard cytotoxic chemotherapy, in stark contrast to those with non-LOP <i>POLE</i> mutations.
Authors
- Michael J. Overman (ORCID: https://orcid.org/0000-0001-5377-135X)
- Scott Kopetz (ORCID: https://orcid.org/0000-0001-9647-3416)
- John Paul Shen (ORCID: https://orcid.org/0000-0003-4588-2775)
- Saikat Chowdhury (ORCID: https://orcid.org/0000-0002-0783-3959)
- Michael G. White (ORCID: https://orcid.org/0000-0001-5022-5505)
- Francesca Bergamo (ORCID: https://orcid.org/0000-0002-8795-4653)
- Mohammad A. Zeineddine (ORCID: https://orcid.org/0000-0001-8075-765X)
- Fadl A. Zeineddine (ORCID: https://orcid.org/0000-0002-0180-0785)
- Sara Lonardi (ORCID: https://orcid.org/0000-0002-7593-8138)
- Abdelrahman Yousef (ORCID: https://orcid.org/0000-0001-7761-8149)
- Timothy Anthony Yap (ORCID: https://orcid.org/0000-0002-2154-3309)
- Giulia Maddalena (ORCID: https://orcid.org/0000-0002-1714-1171)
Institutions
- University of New Mexico Hospital (US)
- Texas Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Padua (IT)
- Texas A&M University System (US)
- Istituto Oncologico Veneto (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1136/jitc-2025-012190
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Conquer Cancer Foundation
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Cancer Prevention and Research Institute of Texas
- BeiGene
- Genentech
- EMD Serono
- National Cancer Institute